Vivosim labs inc VIVS.US Overview Analysis
VIVS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
VIVS Current Performance
1.54%
Vivosim labs inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to VIVS
- IBO Impact biomedical incValue -Trend 2Swing Trading 4Whale Interest -Dividend 1See more
VIVS Profile
VivoSim Labs, Inc., formerly Organovo Holdings, Inc., is a clinical-stage biotechnology company. The Company is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. It focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). Its proprietary technology is used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.